drugset

drugset / Trial / NCT00421278

The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

NCT00421278 ↗

Phase 2 Completed 180 enrolled Merck Sharp & Dohme LLC

RandomizedSingle-groupOpen-labelDiagnostic

Summary

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

Timeline

Start: 2006-11
Primary completion: 2006-12
Completion: 2007-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SETILEUTON	Small molecule	100 mg	Oral

Indications